Monoclonal Antibody (undisclosed)
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
PreclinicalActive
Key Facts
Indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase
Preclinical
Status
Active
Company
About MetaCurUm Biotech
MetaCurUm Biotech is a preclinical-stage company developing a first-in-class antibody targeting a specific oncogenic TGFβ pathway to inhibit metastasis, addressing a critical unmet need in aggressive cancers. Its lead indication is metastatic castration-resistant prostate cancer, with a pipeline intended for breast, lung, kidney, and endometrial cancers. The company, a Umeå University spin-off, is backed by non-dilutive Swedish innovation grants (Vinnova) and is led by a team with deep drug development and scientific expertise. Its strategy combines a novel therapeutic mechanism with a precision medicine approach through parallel biomarker development.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tomivosertib | eFFECTOR Therapeutics | Phase 2 |
| Gedatolisib + Darolutamide | Celcuity | Phase 1b/3 |
| SNP-101 (estimated) | SmartNuclide Biopharma | Phase 1 |
| AB001 (²¹²Pb-NG001) | ARTBIO | Phase 1/2 |
| AB-3028 | Arsenal Biosciences | IND-Enabling |
| PRO CAR-201A | PromiCell | Phase 1 |
| PRO CAR-202 | PromiCell | Preclinical |
| FG-3246 | Kyntra Bio | Phase 2 |
| PROVENGE (sipuleucel-T) | Dendreon | Approved |
| RP12146 | Rhizen Pharmaceuticals | Phase 1b |
| ModraDoc006/r | Modra Pharmaceuticals | Phase 2b |
| SYNC-T | Syncromune | Phase 2 |